Literature DB >> 3308192

Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study.

C Marcocci1, L Bartalena, M Panicucci, C Marconcini, F Cartei, G Cavallacci, M Laddaga, G Campobasso, L Baschieri, A Pinchera.   

Abstract

Combined therapy with systemic corticosteroids and orbital cobalt radiotherapy has been shown to be an effective treatment of severe Graves' ophthalmopathy. The potentially serious side-effects of large doses of systemic corticosteroids prompted us to evaluate the use of retrobulbar corticosteroids instead of systemic corticosteroids. Forty-four patients with active Graves' ophthalmopathy were given orbital cobalt irradiation (total dose 2000 rads) and retrobulbar methylprednisolone acetate (14 bilateral injections at 20-30 d intervals). The degree of ocular involvement and responses to treatment were evaluated by numerical scoring (ophthalmopathy index, OI) and clinical assessment. Excellent or good responses were observed in 11 out of 44 patients (25%), 24 (55%) showed slight responses, and no change was found in 9 patients (20%). The initial OI mean score was 5.9; the final score was 3.2, with a change of -2.7 (P less than 0.001). Regression or partial improvement was observed in most cases (35/44, 80%) with soft tissue changes, and in all 9 cases with sight loss due to optic neuropathy. Proptosis, corneal lesions and extra-ocular muscle involvement were less responsive, since regression or partial improvement was observed in 39% (12/31), 50% (8/16) and 31% (13/42), respectively. No major side-effects were observed. The effects of this type of therapy and those obtained by combined therapy with systemic corticosteroids and orbital radiotherapy were compared in two groups of 30 patients each, randomly assigned to either treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3308192     DOI: 10.1111/j.1365-2265.1987.tb00836.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  20 in total

Review 1.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

3.  DEGRO practical guidelines for the radiotherapy of non-malignant disorders - Part IV: Symptomatic functional disorders.

Authors:  Gabriele Reinartz; Hans Theodor Eich; Fabian Pohl
Journal:  Strahlenther Onkol       Date:  2014-12-09       Impact factor: 3.621

Review 4.  Immunosuppressant therapy of thyroid eye disease.

Authors:  G Kahaly; J Beyer
Journal:  Klin Wochenschr       Date:  1988-11-01

5.  Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy.

Authors:  P Kendall-Taylor; A L Crombie; A M Stephenson; M Hardwick; K Hall
Journal:  BMJ       Date:  1988-12-17

6.  Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone.

Authors:  R Ebner; M H Devoto; D Weil; M Bordaberry; C Mir; H Martinez; L Bonelli; H Niepomniszcze
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

7.  Update on the medical treatment of Graves' ophthalmopathy.

Authors:  Gregory J Griepentrog; James A Garrity
Journal:  Int J Gen Med       Date:  2009-12-29

8.  Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.

Authors:  C Marcocci; L Bartalena; F Bogazzi; G Bruno-Bossio; A Lepri; A Pinchera
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

9.  Medical management of thyroid eye disease.

Authors:  Dawn D Yang; Mithra O Gonzalez; Vikram D Durairaj
Journal:  Saudi J Ophthalmol       Date:  2010-10-26

10.  Update on thyroid eye disease and management.

Authors:  Erick D Bothun; Ryan A Scheurer; Andrew R Harrison; Michael S Lee
Journal:  Clin Ophthalmol       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.